A Look at Travere Therapeutics’s Valuation Following Positive Phase 3 FILSPARI Data in FSGS

Travere Therapeutics (TVTX) just released new findings from its Phase 3 DUPLEX Study, showing that FILSPARI treatment helped FSGS patients achieve meaningful reductions in proteinuria compared to the existing standard of care.

See our latest analysis for Travere Therapeutics.

The excitement from Travere’s Phase 3 DUPLEX Study update comes after a robust rally for the stock, as the one-month share price return surged 36.7% and the 90-day gain climbed to an impressive 90.5%. Adding to the momentum, third-quarter results showed a dramatic revenue and earnings turnaround, fueling optimism about both short-term potential and the company’s long-term track record, given an 83.4% total shareholder return over the past year.

If you’re interested in other biopharma companies driving innovation, now is a great moment to explore the market’s strongest ideas through our See the full list for free.

Yet with shares soaring and the latest data driving renewed optimism, the key question for investors now is whether Travere Therapeutics remains undervalued at current levels or if the recent surge means that future growth is already priced in.

Most Popular Narrative: 10.7% Undervalued

According to the most widely followed narrative, Travere Therapeutics’ fair value estimate of $38.50 is approximately 11% above the recent market close of $34.38. This suggests there may still be upside if the story plays out as forecast. The fair value rests on strong regulatory catalysts and expectations of continued product momentum, setting the stage for potential surprises.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market. If approved, this will create a new, high-margin revenue stream and significantly expand the company's addressable market.

Read the complete narrative.

Ready to discover what could trigger a major re-rating? The narrative is built on ambitious growth, sharply accelerating margins, and a forward valuation metric biotech investors rarely see. What is fueling these high expectations? Find out what makes this forecast so bold.

Result: Fair Value of $38.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, new competition and any unexpected regulatory setbacks could rapidly change the outlook. These factors pose real risks to Travere’s growth story ahead.

Find out about the key risks to this Travere Therapeutics narrative.

Build Your Own Travere Therapeutics Narrative

If you want to dive deeper, challenge these forecasts, or simply see what your own research uncovers, you can put together your own perspective in just a few minutes with Do it your way

A great starting point for your Travere Therapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Smart investors always keep their options open, so don’t miss your chance to uncover next-level opportunities from these powerful stock screens tailored to the current market.

• Capture high yields and steady growth as you evaluate income opportunities using these 16 dividend stocks with yields > 3% for stocks offering robust dividends above 3%.
• Supercharge your portfolio by targeting innovation-focused companies. Start with these 25 AI penny stocks to spot early movers in artificial intelligence.
• Add a layer of resilience and upside with undervalued picks by scanning these 865 undervalued stocks based on cash flows for stocks identified as potential bargains based on strong cash flow analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com